Relationship of Helicobacter pylori CagA(+) status to gastric juice vitamin C levels

European Journal of Clinical Investigation

Volumn 29, Issue 1, 1999, Pages 56-62

  Rokkas, T ^a,c   Liatsos, C ^a   Petridou, E ^a   Papatheodorou, G ^a   Karameris, A ^a   Ladas, S D ^b   Raptis, S A ^b  

^a 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c 401 Army General Hospital ^*  (Greece)

Author keywords

Antioxidant factors; CagA serology; Gastritis; Helicobacter pylori infection

Indexed keywords

ASCORBIC ACID;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GASTRITIS; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; STOMACH JUICE;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ASCORBIC ACID; BACTERIAL PROTEINS; BLOTTING, WESTERN; CHRONIC DISEASE; FEMALE; GASTRIC JUICE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0033007156     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00432.x     Document Type: Article

References (49)

1. 1 Mirvish SS, Wallcave L, Eagen M, Shubic RP. Ascorbate-nitrite reaction: possible means of blocking the formation of carcinogenic N-nitroso compounds. Science 1972;177:65-8.
2. 2 Ohshima H, Bartsch H. Quantitative estimation of endogenous nitrosation in humans by N.nitrosoproline excreted in urine. Cancer Res 1981;41:3658-62.
3. 3 Mirvish SS. Effects of vitamin C and E on N-nitroso compound formation, carcinogenesis and cancer. Cancer 1986; 58 (Suppl.):1842-50.
4. 4 Kyrtopoulos SA. Ascorbic acid and the formation of N-nitroso compounds: possible role of ascorbic acid in cancer prevention. Am J Clin Nutr 1987;45:1344-50.
5. 5 Haenszel W, Kurihara M, Seg M, Lee RK. Stomach cancer among Japanese in Hawaii. J Natl Cancer Inst 1972;49:969-88.
6. 6 Drake IM, Davies MJ, Mapstone NP, et al. Ascorbic acid may protect against human gastric cancer by scavenging mucosal oxygen radicals. Carcinogenesis 1996;17:559-62.
7. 7 Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric campylobacter infection and gastroduodenal disease. Med J Aust 1985;142:439-44.
8. 8 Rokkas T, Sladen G. Infection with Campylobacter pylori. J Royal Coll Phys London 1988;22:97-100.
9. 9 Rokkas T, Pursey C, Uzoechina E, et al. Campylobacter pylori and non-ulcer dyspepsia. Am J Gastroenterol 1987;82:149-52.
10. 10 Rokkas T, Pursey C, Uzoechina E, et al. Non-ulcer dyspepsia and short term De-Nol therapy, a placebo controlled trial with particular reference to the role of Campylobacter pylori. Gut 1988;29:1386-91.
11. 11 Graham D. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
12. 12 Raws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233-5.
13. 13 Graham D. Pathogenic mechanisms leading to Helicobacter pylori-induced inflammation. Eur J Gastroenterol Hepatol 1992;4 (Suppl. 2):S9-S16.
14. 14 Forman D, Newell DG, Fullerton F, et al. Association between infection with H. pylori and risk of gastric cancer. Evidence from a prospective investigation. Br Med J 1991;302:1302-5.
15. 15 Parsonnet J, Friedman GD, Vandersteen DP, et al. H. pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-35.
16. 16 Nomura A, Stemmerman GN, Chyou PH, et al. H. pylori and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-36.
17. 17 Talley NJ, Zinsmeister AR, Weaver A, et al. Gastric adenocarcinoma and H. pylori infection. J Natl Cancer Inst 1991;83:1734-39.
18. 18 THE EUROGAST Study Group. An. international association between Helicobacter pylori infection and gastric cancer: an international study. Lancet 1993;341;1359-62.
19. 19 Hansson LE, Engstrand L, Nyren O, et al. Helicobacter pylori infection: Independent risk indicator of gastric adenocarcinoma. Gastroenterology 1993;105:1098-103.
20. 20 Sobala GM, Schorah CJ, Shires S, et al. Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations. Gut 1993-34:1038-41.
21. 21 Banerjee S, Hawksby C, Miller S, Dahill S, Beattie AD, McColl KE. Effect of Helicobacter pylori and its eradication on gastric juice ascorbic acid. Gut 1994;35:317-22.
22. 22 Rokkas T, Papatheodorou G, Karameris A, Mavrogeorgis A, Kalogeropoulos N, Giannikos N. Helicobacter pylori infection and gastric juice vitamin C levels. Impact of eradication. Dig Dis Sci 1995;40:615-21.
23. 23 Covacci A, Cencini S, Bungoli M, et al. Molecular characterization of the 128kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci 1993;90:5791-5.
24. 24 Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strain possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111-5.
25. 25 Marshall BJ, Warren JR, Francis GJ, Langton SR, Goodwin CS, Blincow ED. Rapid urease test in the management of Campylobacter pyloridis associated gastritis. Am J Gastroenterol 1987;82:200-10.
26. 26 Rokkas T, Pursey C, Simmons NA, Filipe MI, Sladen G. Rapid urease test in the diagnosis of Campylobacter pyloridis infection. Hell J Gastroenterol 1988;1 (Suppl. 1):85.
27. 27 Potters HVPJ Loffeld RJLF, Stobbering E, Van Spreeuwel JP, Arends JW. Rapid staining of Campylobacter pyloridis. Histopathology 1987;11:1223.
28. 28 Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996;20:1161-81.
29. 29 Xiang Z, Censini S, Bayeli PF, et al. Analysis of expression of CagA and Vaca virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that cagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995;63:94-8.
30. 30 Brown PW, Hollander M. Statistics. A biomedical introduction. Wiley series in probability and mathematical statistics. New York: John Wiley 1977.
31. 31 Mai VE, Perez-Perez GI, Wahl LM, Wahl SM, Blaser DD. Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism. J Clin Invest 1991;87:894-900.
32. 32 Sipponen P. Long-term consequences of gastroduodenal inflammation. Eur J Gastroenterol Hepatol 1992;4 (Suppl. 2):S25-S9.
33. 33 Filipe MI, Jass JR. Intestinal metaplasia subtypes and cancer risk. In: Filipe MI, Jass JR, editors. Gastric carcinoma. Edinburgh: Churchill Livingstone; 1986.
34. 34 Rokkas T, Filipe MI, Sladen G. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991;32:1110-3.
35. 35 Correa P, Haenzel W, Cuello C, Archer M, Tannenbaum SA. model for gastric cancer epidemiology. Lancet 1975;ii:58-60.
36. 36 Correa P. Is gastric cancer an infectious disease? N Engl J Med 1991;3251170-71.
37. + Helicobacter pylori strains. Lab Invest 1995;91:760-70.
38. 38 Crabtree JE, Farmery SM. Helicobacter pylori and gastric mucosal cytokines: evidence that cagA positive strains are more virulent. Lab Invest 1995;73:742-5.
39. 39 Van der Hulst RWM, Van der Ende A, Dekker FW, et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA. A prospective one year follow-up study. Gastroenterology 1997;113:25-30.
40. 40 Beales IL, Crabtree JE, Scunes D, Covacci A, Calam J. Antibodies to CagA protein are associated with gastric atrophy in Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1996;8:645-9.
41. 41 Rokkas T, Liatsos C, Petridou E, Papatheodorou G, Karameris A. Atrophic gastritis and intestinal metaplasia in Helicabacter pylori infection: The role of the CagA phenotype. Endoscopy 1997;29:E36.
42. 42 Sobala GM, Schorah CJ, Sanderson M, et al. Ascorbic acid in the human stomach. Gastroenterology 1989;97:357-63.
43. 43 Cover TL, Glupczynski Y, Lage AP, et al. Serologic detection of infection with cagA (+) Helicobacter pylori strains. J Clin Microbiol 1995;33:1496-500.
44. 44 Sozzi M, Valentini M, Figura N, et al. Atrophic gastritis and intestinal metaplasia in Helicobacter pylori infection: The role of CagA status. Am J Gastroenterol 1998;93:375-9.
45. 45 Xiang Z, Bugnoli M, Ponzetto A, et al. Detection in an enzyme immunoassay of an immune response to a recombinant fragment of the 128 kilodalton protein (CagA) of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1993;12:739-45.
46. 46 Ponzetto A, Soldati T, De Giuli M. Helicobacter pylori screening and gastric cancer. Lancet 1996;348:758.
47. 47 Munoz N, Oliver W, Sobala GM, de Sanjose S, Cano E, Peraza S. Prevalence of Helicobacter pylori infection and effect of anti-oxidants in a high risk population for gastric cancer in Venezuela. Ital J Gastroenterol 1991;23 (Suppl. 2):15.
48. 48 O'Connor HJ, Schorah CJ, Habibzedan N, Axon ATR, Cockel R. Vitamin C. in the human stomach: relationship to gastric pH, gastroduodenal disease and possible sources. Gut 1989;30:436-42.
49. 49 Newill A, Habibzedah N, Bishop N, Schorah CL. Plasma levels of vitamin C components in normal and diabetic subjects. Ann Clin Biochem 1984;21:488-90.